- Ensure the correct functioning of the site
- Provide you the best service
- Enhance your user experience
- Optimize our website
Learn more in cookies statement & settings
Prof. François Goldwasser
Presentation Roadmap/ Summary
Sarcopenia has emerged as an independent prognostic factor in oncology. It is also a clinical biomarker of vulnerability. Sarcopenia is favored both by reduced ingesta and/or inflammation. Reduced muscle mass is also responsible for reduced lean body mass and alterations of the pharmacokinetics of anticancer agents. Moreover, the calculated creatinine clearance, especially in sarcopenic overweight patients result in an overestimation of the renal function and overexposure to anticancer treatments. Patients with sarcopenia experience more acute limiting toxicity. Careful attention to muscle mass prior to initiate anticancer therapy is necessary to personalize therapies and optimize benefit/risk ratio.
At the conclusion of the presentation, the participant will be able to:
Key Takeaways/ Fast Facts
Using this link will let you leave a website of Fresenius Kabi Deutschland GmbH (“Fresenius Kabi”) or to a different domain under the control of Fresenius Kabi. In the event that the linked site is not under the control of Fresenius Kabi but under the control of a third party or an affiliate in the Fresenius group of companies, Fresenius Kabi shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Fresenius Kabi of the site.
Do you want to continue?